Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.61 |
| ▸ | PARP1 | P09874 | 3/20 | 0.58 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | RBP4 | P02753 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20287859 | 0.89 | HRH4 (0.56) | AKR1C3PARP1HRH4HRH3POLB | |
| SCHEMBL30526269 | 0.89 | HRH4 (0.56) | AKR1C3PARP1HRH4HRH3POLB | |
| SCHEMBL13548607 | 0.85 | AKR1C3 (0.66) | AKR1C3HRH4HRH3RBP4POLB | |
| SCHEMBL29991244 | 0.81 | KMT2A (0.55) | PARP1HRH4HRH3 | |
| SCHEMBL21235453 | 0.81 | KMT2A (0.55) | PARP1HRH4HRH3 | |
| SCHEMBL25530389 | 0.81 | KMT2A (0.55) | PARP1HRH4HRH3 | |
| SCHEMBL22395224 | 0.81 | PARP1 (0.49) | AKR1C3PARP1HRH4RBP4 | |
| SCHEMBL22395218 | 0.81 | PARP1 (0.49) | AKR1C3PARP1HRH4RBP4 | |
| SCHEMBL29465410 | 0.81 | HRH4 (0.68) | AKR1C3HRH4HRH3POLBSMN1; SMN2 | |
| SCHEMBL2353523 | 0.81 | HRH4 (0.68) | AKR1C3HRH4HRH3POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365195-B2 | Atypical inhibitors of monoamine transporters; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210024523-A1 | ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024523-A1 | ATYPICAL INHIBITORS OF MONOAMINE TRANSPORTERS; METHOD OF MAKING; AND USE THEREOF | SLC18A2, SLC6A3, SLC6A4 | AKR1C3 2252/4885PARP1 2288/4885HRH4 1705/4885 |
| US-11365195-B2 | Atypical inhibitors of monoamine transporters; method of making; and use thereof | SLC18A2, SLC6A3, SLC6A4 | AKR1C3 2252/4885PARP1 2288/4885HRH4 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.